U.S. Interactive Media and Services Stock News

NYSE:CRL
NYSE:CRLLife Sciences

Charles River Laboratories NYSE CRL Quarterly Profit Streak Tests Bearish Profitability Narrative

Charles River Laboratories International (CRL) has just posted its FY 2025 third quarter numbers, with revenue of US$1,004.9 million and basic EPS of US$1.11, against a backdrop where trailing 12 month results still reflect a net loss on EPS. The company has seen quarterly revenue move between US$984.2 million and US$1,032.1 million over the first half of FY 2025, with basic EPS ranging from US$0.50 to US$1.06. Trailing 12 month revenue sits at about US$4.0 billion paired with a net loss of...
NYSE:CFR
NYSE:CFRBanks

Cullen Frost Bankers Dividend Track Record Underpins Earnings And Income Appeal

Cullen/Frost Bankers (NYSE:CFR) highlights a robust dividend record, with a pattern of regular increases that outpaces many peers. The company presents this dividend profile as evidence of sustained financial strength and a positive outlook for future earnings. The bank indicates potential for further dividend growth, reinforcing its appeal for income focused shareholders. Cullen/Frost Bankers, a Texas based regional bank, is putting its dividend front and center at a time when many...
NYSE:CBU
NYSE:CBUBanks

Reassessing Community Financial System (CBU) After Recent Share Price Swings

If you are wondering whether Community Financial System is priced fairly at around US$63.92, taking a closer look at its valuation metrics can help you see what the market might be factoring in. The stock has had mixed short term moves, with a 3.6% decline over the last 7 days, a 3.5% return over the last 30 days, and a 10.0% return year to date, while the 1 year return sits at 1.3% and the 3 year return at 18.8%. Recent coverage of Community Financial System has focused on its position...
NYSE:LBRT
NYSE:LBRTEnergy Services

Liberty Energy Targets Data Center Power And Electric Frac Earnings Shift

Liberty Energy (NYSE:LBRT) is expanding into distributed power generation aimed at gigawatt scale data center demand through its Liberty Power Innovations unit. The company is also advancing its position in electric fracking technology, focusing on lower emissions and high power efficiency at the wellsite. Together, these initiatives reflect a material shift beyond traditional oilfield services into energy support for digital infrastructure. Liberty Energy, known primarily for its hydraulic...
NYSE:SVV
NYSE:SVVMultiline Retail

Is It Time To Reconsider Savers Value Village (SVV) After Recent Share Price Pullback?

If you are wondering whether Savers Value Village is fairly priced or if the market is missing something, this article will walk you through what the current share price might be implying about its underlying worth. The stock most recently closed at US$10.62, with returns of 1.3% over 30 days, a 12.4% gain year to date, and a 5.2% decline over the past year that may have shifted how investors think about its risk and potential. Recent coverage has focused on Savers Value Village as a...
NasdaqGS:CARG
NasdaqGS:CARGInteractive Media and Services

Exploring 3 High Growth Tech Stocks In The US Market

As the U.S. stock market kicks off February with a robust performance, highlighted by significant gains in major indices such as the Dow Jones Industrial Average and S&P 500, investors are closely watching the tech sector for potential high-growth opportunities. In this dynamic environment, identifying promising tech stocks involves considering factors like innovation, market demand, and adaptability to current economic conditions.
NYSE:MGM
NYSE:MGMHospitality

3 Stocks Estimated To Be Undervalued By Up To 49.2%

As February begins, the U.S. stock market has shown notable strength with major indices like the Dow Jones Industrial Average and S&P 500 posting significant gains, reflecting optimism among investors despite ongoing economic uncertainties. In such a vibrant market environment, identifying undervalued stocks can be particularly appealing as they may offer potential for growth at a discounted price.
NYSE:LDI
NYSE:LDIDiversified Financial

Promising Penny Stocks To Consider In February 2026

As February begins, U.S. stock indexes have shown a strong start with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. While larger market trends capture headlines, investors often overlook smaller opportunities such as penny stocks, which despite their vintage name, continue to offer potential for significant returns when backed by solid financials. This article explores three promising penny stocks that combine balance sheet strength with...
NYSE:MCB
NYSE:MCBBanks

Undiscovered Gems in the US Market Featuring 3 Promising Stocks

As the U.S. stock market kicks off February with a notable upswing, highlighted by the Dow Jones Industrial Average's 515-point gain and the S&P 500 nearing record highs, investors are keenly observing how economic shifts and policy changes might impact small-cap stocks. Amidst this backdrop of optimism and strategic trade deals, identifying promising opportunities in lesser-known stocks can be an effective strategy for those looking to diversify their portfolios in today's dynamic market...
NYSE:CNK
NYSE:CNKEntertainment

Cinemark Holdings CNK Margin Slide Challenges Bullish Profitability Narratives After FY 2025 Q3 Results

Cinemark Holdings (CNK) has put up a mixed FY 2025 scorecard so far, with Q3 revenue of US$857.5 million and EPS of US$0.43, following Q2 revenue of US$940.5 million and EPS of US$0.81, and a Q1 loss of US$0.32 per share on revenue of US$540.7 million. The company has seen revenue move from US$734.2 million in Q2 2024 to US$921.8 million in Q3 2024, alongside EPS shifting from US$0.37 to US$1.54 over that stretch, so investors are likely to focus on how current margins stack up against that...
NYSE:FDP
NYSE:FDPFood

Fresh Del Monte Produce (FDP) Earnings Hit One Off Loss That Fuels Margin Debate

Fresh Del Monte Produce (FDP) has reported a mixed set of FY 2025 numbers, with Q3 revenue of US$1.0b and a basic EPS loss of US$0.61, set against trailing 12 month EPS of US$1.65 and net income of US$79.2m. The company has seen quarterly revenue move between US$1.0b and US$1.2b over the last six reported periods, while basic EPS has ranged from a loss of US$0.61 to a high of US$1.18. The latest quarter therefore lands at the weaker end of that spectrum and leaves investors focused on how...
NYSE:CSTM
NYSE:CSTMMetals and Mining

Constellium (CSTM) Margin Compression To 1.4% Tests Bullish Profitability Narratives

Constellium FY 2025 Results: Revenue Steady, Earnings Volatile Constellium (CSTM) just posted another quarter of mixed numbers, with Q3 2025 revenue at US$2.2b, basic EPS of US$0.63 and net income of US$88m. The latest trailing twelve month figures show revenue of about US$8.0b and EPS of US$0.80 alongside a net margin of 1.4% compared to 1.8% the prior year. Over recent quarters, the company has seen revenue move from US$1.8b in Q3 2024 to US$2.2b in Q3 2025. Quarterly EPS has swung from a...
NYSE:TPL
NYSE:TPLOil and Gas

Is It Too Late To Consider Texas Pacific Land (TPL) After Its Sharp Recent Rally

If you are wondering whether Texas Pacific Land is attractively priced or simply expensive for what you get, you are in the right place to unpack what the current share price might be implying. The stock closed at US$440.71, with returns of 6.6% over 7 days, 30.6% over 30 days, 47.9% year to date, while the 1 year return stands at a 5.3% decline and the 3 year and 5 year returns are 129.4% and 268.9% respectively. Recent news around Texas Pacific Land has focused on its position within the...
NasdaqGM:CVAC
NasdaqGM:CVACBiotechs

CureVac (CVAC) Valuation Check After Phase 1 Brain Cancer Vaccine Milestone

Why CureVac's latest trial milestone matters for shareholders CureVac (CVAC) has completed a Phase 1 clinical study for its CVGBM mRNA based brain cancer vaccine in patients with surgically resected glioblastoma or astrocytoma, marking a key early checkpoint for its oncology pipeline. See our latest analysis for CureVac. The completion of the CVGBM Phase 1 study comes after a sharp 14.32% 1 day share price decline and a 19.18% 7 day share price return. However, CureVac’s year to date share...
NYSE:JLL
NYSE:JLLReal Estate

JLL (JLL) Net Margin Improvement Challenges Longstanding Bearish Earnings Narratives

Jones Lang LaSalle (JLL) has put up a busy FY 2025 so far, with Q3 revenue at US$6.5b and basic EPS of US$4.71, alongside trailing 12 month revenue of US$25.3b and EPS of US$13.31 that captures the broader earnings cycle. Over recent quarters the company has seen revenue move from US$5.7b and EPS of US$1.17 in Q1 2025 to US$6.3b and EPS of US$2.37 in Q2, and then to US$6.5b and EPS of US$4.71 in Q3, with a 32.1% earnings increase over the past year setting the backdrop for a business where...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Halozyme Therapeutics (HALO) Q4 Loss On US$451.8m Revenue Tests ENHANZE Profit Narrative

Halozyme Therapeutics (HALO) closed out FY 2025 with fourth quarter revenue of US$451.8 million and a basic EPS loss of US$1.20, compared with Q4 2024 revenue of US$298.0 million and basic EPS of US$1.08. Over the past year, the company has seen quarterly revenue move from US$290.1 million in Q3 2024 to US$354.3 million in Q3 2025, while basic EPS shifted from US$1.08 to US$1.49 over the same quarters, creating a mixed picture for margins as investors digest the latest numbers. See our full...
NYSE:GKOS
NYSE:GKOSMedical Equipment

Glaukos (GKOS) Q4 EPS Loss Of US$2.32 Tests Bullish Profitability Narratives

Glaukos (GKOS) has just posted its FY 2025 numbers with Q4 revenue of US$143.1 million and a basic EPS loss of US$2.32, alongside a trailing twelve month revenue line of US$507.4 million and a basic EPS loss of US$3.28. Over recent quarters, the company has seen revenue move from US$96.7 million in Q3 2024 to US$105.5 million in Q4 2024 and then to US$143.1 million in Q4 2025, while quarterly basic EPS losses shifted from US$0.39 in Q3 2024 to US$0.60 in Q4 2024 and US$2.32 in Q4 2025. For...
NasdaqGM:ATRC
NasdaqGM:ATRCMedical Equipment

AtriCure (ATRC) Turns Q4 Profit And Tests Bullish Earnings Growth Narratives

AtriCure (ATRC) just posted its FY 2025 numbers with Q4 revenue of US$140.5 million and basic EPS of US$0.04 on net income of US$1.8 million, while on a trailing twelve month basis the company remains loss making with basic EPS at US$0.24 and net income of US$11.4 million. The company has seen quarterly revenue move from US$124.3 million in Q4 2024 to US$140.5 million in Q4 2025. Over the same periods, basic EPS shifted from a loss of US$0.33 to a small profit of US$0.04. This sets up a story...
NasdaqGS:ANDE
NasdaqGS:ANDEConsumer Retailing

Andersons (ANDE) Thin 0.9% Net Margin Reinforces Bearish Low Profitability Narrative

Andersons (ANDE) has just wrapped up FY 2025 with fourth quarter revenue of US$2.5 billion, basic EPS of US$1.98 and net income of US$67.4 million. Trailing twelve month revenue came in at about US$11.0 billion with EPS of US$2.81. Over recent quarters the company has seen quarterly revenue move between US$2.5 billion and US$3.1 billion, with EPS ranging from close to flat at US$0.01 in Q1 2025 to US$1.98 in Q4. This creates a backdrop where modest net profit margins and small shifts in...